{"id":"NCT01133704","sponsor":"Dendreon","briefTitle":"Immunotherapy With APC8015 (Sipuleucel-T, Provenge) for Asymptomatic, Metastatic, Hormone-Refractory Prostate Cancer","officialTitle":"A Randomized, Double Blind, Placebo Controlled Trial of Immunotherapy With Autologous Antigen-Loaded Dendritic Cells (ProvengeÂ®, APC8015) for Asymptomatic, Metastatic, Hormone-Refractory Prostate Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2000-05","primaryCompletion":"2003-03","completion":"2005-05","firstPosted":"2010-05-31","resultsPosted":"2010-09-02","lastUpdate":"2010-09-08"},"enrollment":98,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Hormone-Refractory Prostate Cancer"],"interventions":[{"type":"BIOLOGICAL","name":"sipuleucel-T","otherNames":[]},{"type":"BIOLOGICAL","name":"APC-Placebo","otherNames":[]}],"arms":[{"label":"sipuleucel-T (APC8015)","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This is a randomized, double blind, placebo controlled trial of immunotherapy with autologous antigen-loaded dendritic cells (Provenge, APC8015) for asymptomatic, metastatic, hormone-refractory prostate cancer.","primaryOutcome":{"measure":"Overall Time to Disease Progression","timeFrame":"from randomization to 36 months","effectByArm":[{"arm":"Sipuleucel-T (APC8015)","deltaMin":10.9,"sd":null},{"arm":"Placebo","deltaMin":9.9,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.719"}]},"eligibility":{"minAge":"18 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":3},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["35812443","24957547"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":13,"n":65},"commonTop":["Chills","Fatigue","Pyrexia","Back Pain","Arthralgia"]}}